Scientific and Regulatory Policy Committee (SRPC) Review*:
Interpretation and Use of Cell Proliferation Data
in Cancer Risk Assessment by Wood, Charles E. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2015
Scientific and Regulatory Policy Committee
(SRPC) Review*: Interpretation and Use of Cell
Proliferation Data in Cancer Risk Assessment
Charles E. Wood
U.S. Environmental Protection Agency, wood.charles@epa.gov
Renee R. Hukkanen
The Dow Chemical Company
Radhakrishna Sura
The Dow Chemical Company
David Jacobson-Kram
U.S. Food and Drug Administration
Thomas Nolte
Boehringer Ingelheim Pharma GmbH & Co.
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Wood, Charles E.; Hukkanen, Renee R.; Sura, Radhakrishna; Jacobson-Kram, David; Nolte, Thomas; Odin, Marielle; and Cohen,
Samuel M., "Scientific and Regulatory Policy Committee (SRPC) Review*: Interpretation and Use of Cell Proliferation Data in Cancer
Risk Assessment" (2015). Public Health Resources. 318.
https://digitalcommons.unl.edu/publichealthresources/318
Authors
Charles E. Wood, Renee R. Hukkanen, Radhakrishna Sura, David Jacobson-Kram, Thomas Nolte, Marielle
Odin, and Samuel M. Cohen
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/318
Scientific and Regulatory Policy Committee (SRPC) Review*:
Interpretation and Use of Cell Proliferation Data
in Cancer Risk Assessment
CHARLES E. WOOD1, RENEE R. HUKKANEN2, RADHAKRISHNA SURA2, DAVID JACOBSON-KRAM3,4, THOMAS NOLTE5,
MARIELLE ODIN6, AND SAMUEL M. COHEN7
1U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA
2The Dow Chemical Company, Midland, Michigan, USA
3Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
4Current Affiliation: NDA Partners, LLC, Rochelle, Virginia, USA
5Boehringer Ingelheim Pharma GmbH & Co., KG Development, Biberach an der Riss, Germany
6Roche Diagnostics GmbH, PLBT, Penzberg, Germany
7University of Nebraska Medical Center, Omaha, Nebraska, USA
ABSTRACT
Increased cell proliferation is a central key event in the mode of action for many non-genotoxic carcinogens, and quantitative cell proliferation
data play an important role in the cancer risk assessment of many pharmaceutical and environmental compounds. Currently, there is limited unified
information on assay standards, reference values, targeted applications, study design issues, and quality control considerations for proliferation data.
Here, we review issues in measuring cell proliferation indices, considerations for targeted studies, and applications within current risk assessment
frameworks. As the regulatory environment moves toward more prospective evaluations based on quantitative pathway-based models, standardiza-
tion of proliferation assays will become an increasingly important part of cancer risk assessment. To help address this development, we also discuss
the potential role for proliferation data as a component of alternative carcinogenicity testing models. This information should improve consistency of
cell proliferation methods and increase efficiency of targeted testing strategies.
Keywords: cell proliferation; carcinogenesis; mode of action; Ki-67; BrdU; PCNA.
Carcinogenesis is now recognized as a multistep process in
which normal cells progressively acquire a set of core traits that
facilitate and ultimately characterize a malignant state (Hana-
han and Weinberg 2000, 2011). Of these features, perhaps the
most fundamental is a sustained proliferative signal. Disruption
in normal cell proliferation is considered to be a common early
event in the natural history of cancer and a requirement for pro-
gression of a normal cell through the various steps to malig-
nancy. This basic process drives the selection, growth, and
eventual autonomy of neoplastic cells. Biomarkers related to
proliferation play a key role in clinical characterization of dif-
ferent human cancers, including tumor grade, response to ther-
apy, and prognosis (Dowsett et al. 2011; Sestak et al. 2013),
and specific pathways involved in cell proliferation serve as
important targets for a large number of anticancer therapeutics
(Hudis 2007; Cataldo et al. 2011).
Cancer may be defined as poorly controlled cellular
growth arising from errors in DNA. Typically, multiple
(uncorrected) errors in a single cell are required in critical
portions of specific oncogenes or tumor suppressor genes for
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progression to malignancy. Although DNA replication is
highly precise in most cell types, spontaneous errors occur
every time DNA is copied. These errors are the result of pro-
cesses or alterations that occur in the DNA of all cells, includ-
ing oxidative damage, deamination, and adduct formation
(Ames and Gold 1990; Swenberg et al. 2011). The number
of replication errors varies with cell type, and increasing evi-
dence indicates that for such mistakes to result in cancer, they
must occur in progenitor/stem cells of the target tissue (Knudson
1971; Moolgavkar and Knudson 1981; Greenfield, Ellwein, and
Cohen 1984; Flesken-Nikitin et al. 2013; Tomasetti and Vogel-
stein 2015). When errors do occur, they are permanently fixed
during DNA replication in the S phase of the cell cycle. Based
on these principles, an agent can increase the risk of cancer by
directly inducing DNA damage (DNA reactive), by indirectly
promoting errors through increased DNA replication (prolifera-
tive), or by a combination of these events (Knudson 1971; Mool-
gavkar and Knudson 1981; Greenfield, Ellwein, and Cohen
1984; Cohen and Ellwein 1990, 1991). Increased cell division
may thus drive clonal expansion of cells with prior DNA dam-
age, increase the number of target cells for DNA-damaging
agents, or increase the probability of spontaneous genetic errors
(Preston-Martin et al. 1990; EPA 2005).
At a basic level, increased cell proliferation occurs by an
increase in cell births and/or a decrease in cell deaths (Mool-
gavkar and Knudson 1981; Cohen 1995). An increase in cell
births can occur either by mitogenicity resulting from hormonal
or growth factor signals or by cytotoxicity followed by regen-
eration. Direct mitogenicity usually involves interactions with
specific cellular receptors, while cytotoxicity usually involves
necrosis, apoptosis, and/or inflammation, which can result in
local signals leading to regenerative proliferation (Pastoor
et al. 2005; Dragan et al. 2001). Other less common mechan-
isms of increased cell proliferation include removal or inhibi-
tion of suppressive growth signals, resulting in indirect
mitogenesis. A decrease in cell death can occur by inhibiting
apoptosis or cell differentiation, which can lead to an accumu-
lation of target cells even if the rate of cell proliferation
remains the same. Alternatively, greater proliferation at an
early point in time may have an amplifying effect on cell num-
ber later in life (Ellwein and Cohen 1990). In such cases, the
number of cell replications, rather than the replication rate, may
be a key parameter in evaluating overall proliferative activity.
Given the important role of cell proliferation in carcinogen-
esis, quantitative proliferation markers are now widely used in
cancer risk assessment of pharmaceutical and environmental
compounds. When tumor outcomes have been identified in ani-
mals, cell proliferation data are often an important part of the
carcinogenic mode of action (MOA), which characterizes the
requisite key events and/or processes leading to the observed
tumor (Sonich-Mullin et al. 2001; Meek et al. 2003; Boobis
et al. 2006; Meek et al. 2014). For non-genotoxic carcinogens,
these key events often include an increase in proliferation of
the target cell population. Increasingly, proliferation data are
also being incorporated into predictive or prioritization models
of chemical agents with unknown carcinogenic potential
(Cohen 2004, 2010; Sistare et al. 2011). In such models, iden-
tifying true risk signals associated with cancer risk will be an
important challenge in the future requiring greater data
consistency.
The goal of this article is to present unified information
related to the generation, interpretation, and use of proliferation
data. Although our focus here is carcinogenesis, many of the
concepts covered are applicable to other areas of safety assess-
ment. We will review standard methods for measuring cell pro-
liferation in tissue sections and address common sources of
technical and analytical variability. We will also present design
considerations for targeted studies and discuss the use of cell
proliferation data within current risk assessment frameworks.
Finally, we will discuss the potential role for proliferation data
in proposed alternative carcinogenicity testing models and the
importance of standardization in these efforts.
IMMUNOHISTOCHEMICAL MARKERS FOR CELL PROLIFERATION
Commonly used methods for quantifying cell proliferation
in fixed tissue sections are based on chromogenic labeling by
immunohistochemistry (IHC). The most common markers are
5-bromo-20-deoxyuridine (BrdU), Ki-67 (syn. Ki-67, MKi-
67), and proliferating cell nuclear antigen (PCNA). Other less
commonly used proliferation markers detected by IHC (e.g.,
phospho-histone H3), in situ hybridization (e.g., histone mes-
senger RNA), and fluorescence microscopy (e.g., 20-deoxy-5-
ethynyluridine [EdU]) are not discussed here. Rather, our focus
will be on cell labeling index (LI) for BrdU, Ki-67, or PCNA as
a common metric for cell proliferation data. As we will discuss,
these markers identify cells actively moving through the cell
cycle. Their primary use is in assessing changes in proliferation
LI within a population of target cells during a specific window
of time. While increased LIs may in some cases correspond to
preneoplastic or neoplastic changes, these markers do not spe-
cifically identify dysregulated or aberrant proliferation at the
level of an individual cell.
The original in situ measure for proliferating cells in
formalin-fixed paraffin-embedded (FFPE) sections was the
mitotic index, determined by counting the number of mitotic
figures within a given field or population of cells. While tech-
nically simple, this approach is often impractical in studies of
nonneoplastic tissues with low proliferation rates such as liver,
kidney, urinary bladder, or mammary gland. The mitotic phase
of the cell cycle can be up to 10 times shorter than the S phase
(Alberts et al. 2007), leading to low counts per field in many
tissues and requiring extensive and laborious counting. To
improve sensitivity and reduce the number of cells required
to count, tritiated (3H)-thymidine methods were developed
(Hughes et al. 1958). When combined with autoradiography,
this method was the first to allow microscopic counting of cells
that had entered the S phase of the cell cycle (Figure 1A). The
main disadvantages of this method were the use of radioactive
materials and the long duration needed for autoradiography (>2
weeks). In the early 1980s, IHC staining using antibodies to
the synthetic thymidine analog BrdU was introduced as an
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alternative approach for measuring S phase cells without
radioisotopes or autoradiography (Gratzner 1982). Immuno-
staining for BrdU was faster (1–2 days) and provided better
visualization of cells in sections (Figure 1B). These advan-
tages led to widespread adoption of BrdU by the early
1990s as the standard for measuring proliferation LI, particu-
larly in toxicological studies (Leif, Stein, and Zucker 2004).
The major disadvantage of BrdU is the requirement for in-
life labeling, typically by injection or surgical placement of
osmotic pumps, which precludes in situ detection of BrdU
in human tissues and archival nonclinical specimens without
prior BrdU exposure.
To address these limitations, monoclonal antibodies (mAbs)
to PCNA and Ki-67 were developed concurrently in the 1980s
for immunolabeling of proliferating cells without in-life treat-
ment (Gerdes et al. 1983; Figure 1C–D). PCNA is a nonhistone
nuclear protein that acts as a sliding DNA clamp during DNA
replication (Paunesku et al. 2001), while Ki-67 is thought to
function in ribosomal RNA transcription (Bullwinkel et al.
2006). In contrast to BrdU, PCNA and Ki-67 proteins are
expressed by cells in G1, S, G2, and M phases of the cell cycle
but not the G0 phase and thus more accurately measure the
growth fraction (or proliferative ‘‘state’’) of a cell population
(Kurki et al. 1986; Scholzen and Gerdes 2000). Maximal
PCNA expression occurs in the late G1 and S phases (Scholzen
and Gerdes 2000), while Ki-67 levels are low during G1 and
early S phases and progressively increase from mid-S phase
until late M phase, when levels rapidly decline (Lopez et al.
1991; Figure 2A). These 2 markers label virtually all known
cell types across a wide variety of species, allowing for
cross-species comparisons. Expression across multiple stages
of the cell cycle also provides greater dynamic range in LIs
compared to mitotic counts, which may be zero or near zero
in many nonneoplastic tissues.
Early use of PCNA and Ki-67 favored PCNA mainly
because the primary antibody to PCNA (PC10) could be used
on both frozen and FFPE sections, while the original Ki-67
antibody was limited to frozen sections only. This situation
changed with the development of MIB-1 and other Ki-67 mAbs
in the 1990s that could be used on both frozen and FFPE sec-
tions (McCormick et al. 1993). Other evidence showed sensi-
tivity of PC10 to fixation and heat-induced antigen retrieval
(AR) methods and potential functions of PCNA distinct from
cell proliferation (Tahan et al. 1995; Prosperi 1997; Scholzen
FIGURE 1.—Markers of cell proliferation. (A) Tritiated thymidine labeling of mouse hepatocytes. Note dark granules indicating radiolabeled thy-
midine molecules. Hematoxylin and eosin (H&E) background stain, 40 objective magnification. (B) 5-bromo-20-deoxyuridine (BrdU) labeling
of rat colonic crypt epithelial cells. Hematoxylin background stain, diaminobenzidine (DAB) chromogen, 40 objective magnification. (C, D)
Images of Ki-67-labeled mouse hepatocytes before (C) and after (D) automated cell selection. In this example, cells were sorted and color-
coded by nuclear shape, size, and label. Hematoxylin background stain, DAB chromogen, 10 objective magnification.
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and Gerdes 2000), leading to greater use of Ki-67 in human
cancer research and other fields.
Numerous human and rodent studies have shown significant
correlation among BrdU, PCNA, and Ki-67 LIs (Goodson et al.
1998; Thor et al. 1999; Birner et al. 2001; Urruticoechea,
Smith, and Dowsett 2005; Dowsett et al. 2011). Marker LIs
also tend to correlate well with mitotic index in samples with
high enough proliferation rates to get meaningful mitotic
counts, mainly tumor studies (Thor et al. 1999). Notable incon-
sistencies between markers have also been reported. Such dif-
ferences may relate to variations in fixative, antibody, IHC
protocol, tissue type, duration of BrdU exposure, and treatment
conditions, as discussed subsequently (Holt et al. 1997; Tanaka
et al. 2011). In general, Ki-67 labeling appears to correlate
more strongly with BrdU than with PCNA in most tissues
(Urruticoechea, Smith, and Dowsett 2005; Dowsett et al.
2011), while PCNA shows variable correlation with Ki-67 or
BrdU (Muskhelishvili et al. 2003; Eldridge and Goldsworthy
1996).
The relative magnitude of LIs also varies by marker. For
example, BrdU is higher than Ki-67 in some studies but lower
in others, likely as a function of proliferation rate and in-life
BrdU treatment time (Birner et al. 2001; Muskhelishvili et al.
2003). When measured together, LIs for PCNA tend to be higher
than Ki-67 (Muskhelishvili et al. 2003), perhaps due to the non-
proliferation functions of PCNA (Prosperi 1997; Pauneska et al.
2001) or longer half-life for PCNA (~20 hr) compared to Ki-67
(1–2 hr; Bravo and Macdonald-Bravo 1987; Bruno and Darzyn-
kiewicz 1992). Importantly, cell labeling for BrdU increases
with in-life BrdU exposure because all cells passing through the
S phase of the cell cycle retain BrdU. As an example, a recent
study reported BrdU LIs of 6%, 12%, and 23% in the terminal
bronchiolar cells of mice after 1, 2, and 4 weeks of continuous
BrdU infusion, respectively (Kameyama et al. 2014). In contrast,
Ki-67 and PCNA evaluate a more discrete window of prolifera-
tive activity at the time of sample collection. Features of BrdU,
Ki-67, and PCNA markers are summarized in Table 1.
Antibodies to BrdU, PCNA, and Ki-67 are commercially
available for IHC in all standard research species. Anti-BrdU
mAbs are most diverse (Liboska et al. 2012); common clones
include BU20a in mouse and BU-1/75 in rat, but there is wide
variation in anti-BrdU antibodies across studies. For PCNA, the
PC10 clone mouse mAb is most widely used and cross-reacts
with most species tested; however, other clones may be preferred
for mouse tissues to avoid background staining due to nonspeci-
fic binding to endogenous immunoglobulins. For Ki-67, the
MIB-1 antibody widely used for human tissues cross-reacts with
the Ki-67 protein in many nonhuman species (e.g., monkey, dog,
ox, horse, sheep) but not rodents (Birner et al. 2001), for which
other clones are available (e.g., MIB-5 and SP6).
VARIABILITY IN METHODS FOR MEASURING CELL PROLIFERATION
Consistency between laboratories and studies is an impor-
tant issue in evaluating cell proliferation data (Dowsett et al.
2011; Polley et al. 2013; Nolte et al. 2005). Most laboratories
rely upon indirect IHC methods with primary and secondary
antibodies, horseradish peroxidase– or alkaline phosphatase–
conjugated streptavidin labels, commercial chromogens such
as diaminobenzidine (DAB), and counterstaining with hema-
toxylin. Beyond these standard procedures, there may be
important differences across laboratories related to sample
fixation, tissue processing and storage, marker and antibody
selection, IHC equipment, and other technical details of IHC
protocols. Such differences may impact LI readouts. Several
work groups have been formed to address this issue for clinical
applications related to the Ki-67 marker (Dowsett et al. 2011;
Polley et al. 2013). Similar efforts exist for preclinical applica-
tions as well, although to date these have been more limited
(Nolte et al. 2005). In this section, we will briefly consider
pre-analytical sources of variation in LI data.
Sample Preparation
Tissue collection should be one of the initial considerations
for any cell proliferation study. Sampling protocols will vary
FIGURE 2.—Patterns of expression for different cell proliferation mar-
kers. (A) labeling dynamics for 5-bromo-20-deoxyuridine (BrdU), pro-
liferating cell nuclear antigen (PCNA), and Ki-67 across the cell cycle.
Note that these are general patterns that may vary based on cell type.
Broken lines indicate potential die-off (for BrdU) and persistence (for
PCNA). (B) Labeling dynamics for different proliferative responses
over time. Classic patterns include plateau mitogens (e.g., ERa ago-
nists > uterus), burst mitogens (e.g., PPARa agonists > liver), and
regenerative proliferation following cytotoxicity (e.g., chloroform >
kidney), which may appear at acute to chronic time points.
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by experiment and tissue type but should be clearly defined
prior to necropsy to ensure consistency and alignment with
study goals. A technically detailed collection and trimming
protocol will aid in the identification of the same macroscopic
region for each target tissue and increase concordance between
target site and proliferation measurements. For example, if
nasal epithelial tumors were observed in a carcinogenicity
study within a specific region of the nasal turbinates, then it
is critical to analyze this region in the corresponding shorter-
term proliferation study and not an arbitrary region of the nasal
cavity. If mass lesions are observed in the target tissue, these
should be collected separately from grossly normal tissues to
avoid a mixed batch of neoplastic and nonneoplastic samples
resulting in missing or biased data. Cell proliferation LIs from
proliferative lesions (e.g., hyperplastic focus or tumor) should
generally be excluded or analyzed separately frommorphologi-
cally normal areas.
Tissue fixation is another variable to consider in cell prolif-
eration studies. The most widely used fixative for histology is
formalin, which preserves tissue architecture mainly by cross-
linking proteins. These cross-links may mask antigens and
thereby interfere with IHC labeling (Puchtler and Meloan
1985). Prior studies have consistently shown that formalin fixa-
tion for prolonged periods (typically >24 hr) may decrease
BrdU LIs compared to matched frozen samples (McGinley,
Knott, and Thompson 2000). Similar or greater effects have
been reported for PCNA LIs (Tahan et al. 1995; Casasco
et al. 1994). Labeling for Ki-67 (MIB-1 at least) has generally
shown more resistance to formalin fixation effects compared to
BrdU and PCNA, but loss of antigenicity may still occur
(McCormick et al. 1993; Hendricks and Wilkinson 1994;
Benini et al. 1997; Holt et al. 1997; Arber 2002; Otaliet al.
2013). These observations have led to the practice of fixing tis-
sues for IHC initially in 10% buffered formalin (or fresh 4%
paraformaldehyde) for 12 to 24 hr and then transferring them
to 70% ethanol or alternative alcohol-based fixatives that do
not form protein cross-links (McGinley, Knott, and Thompson
2000; Otali et al. 2013). In some instances, fixation directly in
70% ethanol may be optimal (Ohnishi et al. 2007), depending
on the specific requirements of the antibodies used. Ideally,
internal optimization and validation of fixation protocols
should be documented in the operating procedures for each
laboratory. Use of a positive proliferation control reference
group (e.g., treated with a known mitogen for the tissue of
interest) will also help distinguish true negative results from
signal loss related to fixation, especially for studies in which
low control LIs are expected.
The length of time FFPE tissues stay in paraffin block (or
sectioned on slide) prior to IHC staining can also affect antige-
nicity for proliferation markers. Age-in-block is an important
consideration when using archived samples that differ in age
(e.g., tumor case series) or performing a retrospective analysis
of tissue samples from an older study (Greenwell, Foley, and
Maronpot 1993). Prolonged age-in-block can lead to variable
or tissue-specific loss of antigenicity depending on storage con-
ditions and prior tissue processing (Karlsson and Karlsson
2011; Xie et al. 2011). For archival case studies or cross-
study comparisons, it is important to include fixation method
and age-in-block as covariates in the analysis.
Immunolabeling
Potential differences in IHC procedures across laboratories
include the use of automated compared to manual slide stain-
ing, primary antibody dilution, buffer selection, and incubation
times (Nolte et al. 2005). Given this variability, it is critical that
internal optimization and validation of IHC protocols are used
to determine the most appropriate staining conditions (Hen-
dricks and Wilkinson 1994). Reporting full details of these
methods will also facilitate greater concordance between stud-
ies and laboratories and aid in interpretation of unexpected or
marginal treatment effects.
General recommendations for IHC quality control include
negative and positive staining control slides run for each stain-
ing batch. For negative control slides, nonimmune serum from
the same species as the primary antibody is often applied in
place of the primary antibody. For positive controls, a tissue
with high basal proliferation (e.g., intestine, stomach, or lymph
node) from the same animal or study may be run in each batch
or on each slide to confirm appropriate label administration (for
BrdU) and staining. Non-target cells with proliferative activity
(e.g., lymphocytes) may also serve as internal positive controls
for some tissues. For new mAb clones or lots, a dilution series
is recommended to account for any shifts in affinity.
Epitopes masked by fixative cross-links, FFPE processing,
and age-in-block effects can be partially recovered through
TABLE 1.—Summary features for different immunohistochemical proliferation markers.
Feature BrdU PCNA Ki-67
Cellular localization Nuclear Nuclear Nuclear
Label dynamics Incorporated in S phase Expressed in non-G0 phases (peak in late G1/S) Expressed in non-G0 phases (peak in late S/M)
Label duration Persistent Transient (*20 hr half-life) Transient (1–2 hr half-life)
Considerations  In-life exposure
 Direct effects
 DNA denaturation step
required
 Expression window
 Nonspecific expression (e.g., DNA repair)
 greater sensitivity to fixative effects
 Expression window
 Less sensitive to fixation
 Cell cycle dynamics (e.g., arrest)
 Cross-species use
 Cross-species use
Note: BrdU ¼ 5-bromo-20-deoxyuridine; PCNA ¼ proliferating cell nuclear antigen.
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various ARmethods (D’Amico, Skarmoutsou, and Stivala 2009;
Shi, Key, and Kalra 1991; Greenwell, Foley, and Maronpot
1993). While critical to many IHC protocols, the degree of epi-
tope recovery often varies (McGinley, Knott, and Thompson
2000). The most common AR method is heating via microwave,
water bath, or steamer, often with a citrate buffer; alternative
techniques include use of proteolytic enzymes or other chemical
treatments (D’Amico, Skarmoutsou, and Stivala 2009). Impor-
tantly, both heat and chemical AR methods may potentially
increase background labeling (D’Amico, Skarmoutsou, and Sti-
vala 2009; Bak and Panos 1997). General recommendations to
minimize this nonspecific labeling include avoidance of extreme
AR conditions (e.g., heat and pH), inclusion of control condi-
tions for endogenous antigens, and performing initial optimiza-
tion protocols (D’Amico, Skarmoutsou, and Stivala 2009;
Greenwell, Foley, and Maronpot 1993).
An AR issue unique to BrdU IHC is the specificity of anti-
BrdU mAbs for single-stranded DNA. Antibody binding thus
requires a denaturation or degradation step, typically with
hydrochloric acid and/or nuclease digestion. These treatments
can further increase background BrdU staining, alter immunor-
eactivity to other antigens, and disrupt tissue morphology (Kass
et al. 2000; Dover and Patel 1994; Liboska et al. 2012).
Approaches developed to avoid these issues include use of
sodium hydroxide to relax DNA and monovalent copper ions
to create gaps in DNA (Liboska et al. 2012). EdU, which is a
more recently developed thymidine analog, does not require
this denaturation step and is currently used as a fluorescence-
based alternative to BrdU (Mead and Lefebvre 2014).
Quantification of Cell Proliferation Markers
Perhaps the most important source of variation in prolifera-
tion LIs is the method used for measuring positively labeled
cells. For example, a recent interlaboratory reproducibility
study of Ki-67 in the same set of human cancer samples
reported mean LIs from 7% to 24% (Polley et al. 2013). This
wide range was attributed to differences in region selection,
cell counting methods, and subjective thresholds for positive
labeling. Other sources of variation include selection criteria
for specific cell types; tissue heterogeneity and staining hot
spots; the number of fields and cells counted; and digital ima-
ging applications (Dowsett et al. 2011). Variability in cell
counting methods can limit comparisons to historical control
values, inter-study and interlaboratory data comparisons of
treatment effects, and use of proliferation LI data for modeling
applications and clinical and safety assessments. Here we will
briefly review basic counting approaches and discuss consid-
erations that may influence data interpretation and improve
standardization.
The simplest way used to quickly assess the number of pro-
liferating cells is by visual estimation. Typically, arbitrary cate-
gories for percentage of positive cells are preset (e.g., <10%,
10–25%, 25–50%, 50–100%), and one or more pathologists
blindly grade slides according to these categories. Staining
intensity (e.g., 1þ to 4þ) may be included as an additional
descriptor. While expedient, this method is more subjective
than individual cell counts and applicable mainly to tumor sam-
ples with a much greater range of LIs compared to nonneoplas-
tic tissues, which generally have control LI ranges <10% (and
often <1%). Such low values cannot be reliably categorized by
qualitative evaluation.
The most common method for determining LIs in targeted
toxicological studies is cell counting by light microscopy. An
important recommendation for these studies is to use actual cell
counts for the LI (i.e., positive target cells/total target cells
counted) rather than the positive cells per field or unit tissue
area. Percentage-based LIs provide a standardized end point
and avoid bias resulting from changes in cell or tissue size.
Prior to digital imaging, cells were counted manually in real
time using a click counter; today, counts are typically per-
formed on digital images that can be annotated and saved for
reference (Do¨lemeyer et al. 2013). As with IHC staining proto-
cols, there are many different techniques used for manual
counts and limited standardization of methods, which are often
tissue-specific and developed empirically within each labora-
tory. General considerations include field selection, the number
of fields and cells to count, signal thresholds for positive label-
ing, and whether to focus on a specific tissue compartment,
region, or cell type of interest.
Take, for example, a targeted cell proliferation study in the
liver. The following criteria should be determined prior to count-
ing: number of total cells counted per sample (typically1,000),
the objective magnification for imaging (20 or 40), and the
number of fields to be counted (typically 3–6 across 2 or 3 dif-
ferent lobes; Ross et al. 2010). Fields are often selected using
random coordinates or arbitrary assignment, excluding areas
with clear artifacts or lesions (e.g., extensive necrosis, inflamma-
tion, or neoplasia). Adjacent sections stained with hematoxylin
and eosin (H&E) for histopathology may be helpful for identify-
ing lesions in the area to be counted. Morphological cell selec-
tion criteria should also be predetermined to distinguish large
mature hepatocytes from smaller or spindle-shaped cells, which
may or may not represent a hepatocyte lineage or target cell of
interest. Finally, compartmentalization of liver counts into cen-
trilobular, midzonal, and periportal regions may be needed in
some cases to discern a zone-specific effect.
For tissues with potential clustering of proliferative cells,
digital filters may be useful to spread out counts over a larger
area, define regions of interest (ROIs), and reduce the impact of
hot spots. For example, normal intestinal epithelium has a high
background rate of proliferation in the crypt cells but not in
more apical cells. Here it is important to systematically divide
the tissue into crypt and apical compartments and perhaps even
more specific ROIs. For such rapidly proliferating tissues such
as the intestine, morphometric evaluation of crypt size may be a
more sensitive indicator of cell proliferation rather than LI. The
LI may be similar in untreated versus treated intestine, despite
significant expansion of the crypt size and consequently the
number of proliferating cells. Applying digital color thresholds
for positive cells is another important way of increasing consis-
tency and reducing intra- and interobserver variation in cell
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counts. For manual counting, establishing reference images of
borderline weak positive cells prior to data collection are help-
ful in maintaining these thresholds.
Digital image analysis methods now allow for automated
measurement of LIs (van der Loos et al. 2013). Advantages
of this approach include improved efficiency (e.g., decreased
observer time), objectivity (e.g., for positive cell thresholds),
tissue coverage (e.g., with whole slide analyses), and quantita-
tive analytical capabilities (e.g., target cell/ROI selection).
Automated identification of labeled and unlabeled nuclei is
typically based on thresholding functions that partition a digital
image into elements based on pixel intensity values across dif-
ferent color channels. Optimal thresholds for detection of neg-
ative and positive nuclei will vary based on a number of
different pre- and post-processing factors. Thus, analytical pro-
grams are generally specific to a particular laboratory, study, or
even batch of IHC slides within a study. For any automated
counting system, it is important that only the target cell type
of interest is actually counted rather than multiple or all cell
types.
Standardization of image capture and processing (e.g., white
balance, contrast) and internal validation of thresholds (e.g.,
using a comparison of manual and automated LIs) should be
addressed on a case-by-case basis. Tissue-specific considera-
tions include the use of cell size and shape thresholds, establish-
ing ROIs (e.g., to exclude non-target cells or compartments), and
splitting of touching nuclei into separate objects (e.g., in colonic
epithelium). As for manual counts, the sampling parameters
should be clearly defined, and inferences should be limited to the
specific cell populations counted. For IHC staining, it is impor-
tant to optimize counterstaining, since variation here may impact
negative cell counts (e.g., weaker counterstain may inflate LI) or
decrease specificity between labeled and nonlabeled cells. Other
quality control issues relate to management of raw and annotated
digital images as archived data (Do¨lemeyer et al. 2013), partic-
ularly in good laboratory practice (GLP) studies. For example, to
maintain compliance with U.S. Food and Drug Administration
(FDA) electronic record guidelines, software used to generate,
measure, and assess GLP data must have an audit trail and a reli-
able method of electronic storage (FDA 2003).
In some cases, more sensitive stereological approaches may
be needed to detect subtle changes in LI or density of labeled
cells with greater confidence. Stereology allows reconstruction
of the third dimension within an organ using statistical sam-
pling principles and modeling analyses, which are particularly
useful for specialized structures or cell populations (Falca˜o
et al. 2013). Proper stereological methods avoid potential
sources of bias inherent to methods using a limited number
of sections (such as lack of uniformity throughout the organ)
and accommodate changes in organ size for cell density esti-
mates. For proliferation studies, stereological methods may
also be used to capture the number of labeled cells at a whole
organ level, expressed as sum totals or density estimates nor-
malized by organ volume. This type of information is important
for treatments that may significantly affect organ volume and/
or total cell number without altering LI. More detailed reviews
of these approaches are provided elsewhere (Boyce et al.
2010).
CONSIDERATIONS FOR THE DESIGN OF PROLIFERATION STUDIES
Cell proliferation is a dynamic process influenced by many
factors, including the target tissue and cell type, time course of
exposure, model system, and treatment conditions. Experimen-
tal factors such as diurnal variation and whether to fast animals
prior to termination should be addressed, as these can signifi-
cantly alter the LI of some tissues. Proper understanding of
such factors can be important to the quality of data obtained
from targeted proliferation studies. In this section, we will dis-
cuss issues related to study design, focusing on marker selec-
tion, temporal dynamics of marker expression, and model
and statistical considerations.
Marker Selection
The most widely used IHC label for proliferation in precli-
nical in vivo studies is BrdU. Despite being widely considered
as the marker of choice, BrdU is contraindicated in certain tis-
sues and study types. As noted earlier, the major disadvantage
of BrdU for standard applications is the requirement for in-life
labeling either by pulse or continuous exposure. Surgical place-
ment of osmotic pumps can introduce a number of potential
study issues, including loss of animals due to health complica-
tions (e.g., anorexia, infections) and potential effects on other
study parameters influenced by anesthesia and surgery near the
time of sacrifice (e.g., hormonal, metabolic, or inflammatory
markers; Wyatt et al. 1995). Decreased feed intake may in turn
affect dosing of the test article if given via the diet. Administra-
tion of BrdU can be directly toxic when administered at high
doses or for long durations, or in some cases induce prolifera-
tive activity (e.g., in the thymus and adrenal cortex), potentially
confounding experimental results (Nolte et al. 2005). Exposure
of cultured cells to BrdU has also been shown to alter gene
expression, DNA repair, and mutational profiles (Minagawa
et al. 2005; Masterson and O’Dea 2007; Taupin 2007), and thus
BrdU may not be suitable for studies with concurrent genomic
or genetic end points.
Unlike BrdU, Ki-67 and PCNAmarkers do not require in-life
labeling. This allows for retrospective evaluation of archived
samples (e.g., tumor case series) and eliminates potential in-
life marker effects on transcriptomic data. Disadvantages of
PCNA include formalin sensitivity and expression due to func-
tions beyond cell proliferation, including DNA repair and apop-
tosis (Paunesku et al. 2001). Use of PCNA may thus be
contraindicated for proliferation studies of potential DNA-
damaging agents. The longer half-life of PCNA may also mask
a potential treatment effect in tissues with higher background
rates of proliferation by increasing control LIs. Both PCNA and
Ki-67 have discrete windows of expression in the cell cycle and
thus avoid the cumulative labeling of cells seen with BrdU. This
single time point (snap shot) feature may be a disadvantage if
time course dynamics of a potential mitogenic burst effect are
very acute or not known. For example, using a 7-day exposure
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time point for a mitogen that caused an acute burst of prolifera-
tion at day 3 may lead to a false negative result. In cases when
predicted changes are uncertain, multiple time points are recom-
mended. An additional consideration for Ki-67 is the lag effect
relative to the cell cycle (low G1 and high G2 expression), which
could potentially skew expression lower for agents that arrest
cells in G0/G1 and higher for agents that arrest cells in G2/M
(Scholzen and Gerdes 2000; Dowsett et al. 2011). Other effects
such as loss of histone deacetylation have also been shown to
selectively alter Ki-67 expression during mitosis (Xia et al.
2013). Use of an alternate label is recommended if such
marker-specific effects are suspected. For Ki-67 and other label-
ing methods, if there is concern about the results (e.g., apparent
lack of increased LI in the presence of obvious cytotoxicity),
complementary assessment of mitotic rate can be helpful.
In-life BrdU Exposure
As described earlier, frequency and duration of BrdU expo-
sure may have an important impact on LI. To account for var-
iation, BrdU protocols should be optimized for the particular
study type and tissue of interest. For rapidly proliferating tis-
sues (e.g., intestinal or lymphoid tissues), a single exposure
to BrdU will result in labeling of sufficient numbers of labeled
cells to detect a treatment effect. These burst protocols are use-
ful for defining the number of S phase cells over a short time
period (6 hr) but do not provide information on kinetics
(e.g., doubling time). Single-dose protocols may also show
high intra- and inter-day variability, which can be minimized
to some extent by standardizing the time of day that samples
are collected.
In tissues with low proliferative activity, BrdU dosing often
needs to be extended to provide an adequate dynamic range of
labeled cells. Such tissues require continuous exposure to BrdU
achieved through the use of osmotic mini-pumps or frequent
dosing. For these studies, a 3- to 7-day exposure typically
results in labeling of sufficient numbers of proliferating cells
within target and control tissues. Continuous exposure proto-
cols provide feedback on the total proliferative activity during
administration but do not distinguish between cells in S phase
and those that have exited S phase during the labeling period.
Compared to pulse-labeling, continuous exposure protocols are
better controlled for intra- and inter-day variability. Since
labeling is a function of BrdU exposure time, LIs from studies
with variable labeling-exposure durations generally should not
be directly compared. If such comparisons are necessary, a
division rate can be used to correct for labeling exposure
(Moolgavkar and Luebeck 1992). In some tissues such as urin-
ary bladder, placement of a subcutaneous mini-pump can pro-
duce sufficient stress to alter the LI. Under such circumstances,
pulse-labeling or use of Ki-67 may be preferable (Cohen et al.
2007).
Model Considerations
Model selection should be tailored to the particular goals of
the study. For targeted proliferation studies designed to address
carcinogenic MOA, the species, strain, and sex should match
that of the bioassay in which the tumor outcome was observed.
In addition, the source of animal, diet, and starting age of the
animals should be matched as much as possible. Similarly, in
investigative studies, the experimental models should match
as closely as possible the life stage and hormonal context of the
human disease being studied. Diet considerations include calo-
ric intake and soy isoflavone exposure from chow-based for-
mulas, which can potentially influence cell proliferation
(Allred et al. 2004). In general, isoflavone-free diets should
be used. Finally, specialized protocols should be consulted
when using proliferation markers in alternative models such
as small fish (Law 2001; Santhakumar et al. 2012).
Tissue-specific Dynamics
Tissues from adult control animals exhibit a wide variation
in normal background rates of cell proliferation, from constant
high LIs (e.g., hematopoietic cells, intestinal epithelial cells,
male germ cells) to low or barely detectable LIs (e.g., cerebro-
cortical neurons, cardiomyocytes). Given the many variables
that may affect LIs, it is difficult to provide specific back-
ground rates of proliferation for most individual tissues or cells.
However, a working knowledge of control LI ranges previously
reported in the literature can help identify variance estimates
for sample size determination and potential technical problems
when they occur. For example, control hepatocyte LIs in a
study of young adult B6C3F1 male mice using osmotic mini-
pumps with 3-day administration are typically <3%; values
much higher than this may be cause to question the validity
of methods or data (e.g., nonspecific staining).
Temporal Dynamics
The time course of a mitogenic or regenerative LI response
is often cell- or tissue-specific. Schematic examples are given
in Figure 2B, which shows hypothetical proliferation LI
curves for an acute burst mitogen (e.g., peroxisome
proliferator-activated receptor a [PPARa] agonist in liver),
a plateau mitogen (e.g., estrogen in endometrial glands), and
a delayed regenerative proliferative response (e.g., chloro-
form in kidney tubular epithelium). Note that the timing of
initial response and ‘‘decay’’ following an acute burst may
vary by tissue, agent, and dose. Understanding these types
of time course dynamics for the target tissue of interest is
an important element of study design. For example, prolifera-
tion studies in the liver often include a 3- to 7-day time point
to detect acute mitogenic effects with a 28-day time point to
confirm reversal of the burst and to detect any delayed regen-
erative effects (Ross et al. 2010). Data from a single 14-day
time point in between mitogenic and regenerative prolifera-
tion windows may be more difficult to interpret. Other tissues
such as lung may also require short <7-day windows for
detection of acute proliferation bursts (Strupp et al. 2012;
Cruzan et al. 2013). For tissues lacking well-established
responses, pilot studies using known positive mitogenic con-
trols may be needed to establish temporal dynamics.
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Dose Considerations
For known tumorigens, a suitable dose range should allow
evaluation of concordance between any effects on prolifera-
tion LI and tumorigenic responses in the corresponding carci-
nogenicity study (e.g., EPA 2005). For proliferation-based
MOAs, concordance would be supported by a proliferative
response at or below the tumorigenic dose level. In contrast,
a single-dose proliferation study at an exposure above the car-
cinogenic dose would not be considered adequate. If avail-
able, results of other toxicity studies on the agent of interest
should be reviewed to avoid systemic toxicity or overt cyto-
toxic effects in the target tissue. As noted elsewhere, cytotoxi-
city with regenerative proliferation may potentially mask a
direct mitogenic effect and increase variability in LI data
(Wood et al. 2014).
Tissue Compartmentalization
Measurement of LIs should be restricted to target compart-
ments and cell types of interest within a given tissue type. In
many cases, these compartments or cell types can be reliably
identified by morphology (e.g., mammary gland lobular and
ductal epithelium). However, different protocols and/or studies
may still be required to accurately assess LIs across cell types.
For example, within the kidney, proliferation LI responses vary
between glomeruli and tubules and between proximal and dis-
tal tubules (Umemura et al. 2004). If the proximal tubules are
targeted, a 3-day BrdU labeling-exposure would be adequate
based on proliferation rates of the epithelium. If the collecting
ducts are targeted, the labeling-exposure should be longer (>7
days; Nolte et al. 2005).
For counting, it is often challenging to obtain LIs for cell
types that are difficult to identify histologically. Examples
include C-cells in the thyroid gland, endothelial cells in liver
or adipose tissue, and smaller non-hepatocyte cell populations
in the liver (Nolte et al. 2005; Ohnishi et al. 2007). In such
cases, a double-labeling IHC approach may be required using
a proliferation label in combination with a cell-specific mar-
ker (e.g., calcitonin for C-cells, CD31 for endothelial cells,
and CD68 for Kupffer cells). This type of approach may also
be helpful in mechanistic studies for relating proliferative
responses to upstream molecular events (e.g., receptor expres-
sion). Without a double label, it is important to clearly specify
what visual or computer-assisted cell selection criteria were
used to identify target cells of interest.
Other Statistical Considerations
As with other end points, sample size and effect variance
will determine the statistical power of LI results. Expected
treatment effect (change versus control) as well as control LIs
will inform the number of samples and cells to count per sam-
ple (Morris 1993). Sample size is the primary driver for power,
so power decreases as sample size is reduced, even if more cells
are counted per sample. In general, for a given fold-change in
LI from control, larger sample sizes are needed to meet power
thresholds when the control LIs are lower. Similarly, treatment-
induced changes will be harder to detect when LIs are lower,
and thus more cells per sample should be counted to reduce
variance and increase power in this case (Morris 1993). In a
simple example provided by Morris (1993), a 2-fold increase
in LI when the control value is near 5% was comparable in
power to a 3.5-fold increase in LI when the control value was
near 1%.
These concepts are illustrated in the Ki-67 LI data sets
shown in Figure 3. Note that labeling data in both sets are
asymmetrically distributed (clumped toward zero) with nonho-
mogeneous variance across groups. Analysis of group differ-
ences thus require nonparametric analysis, which is typical
for LI data. This skew does not strongly influence power out-
comes, which can be calculated using either a t-test or a rank
sum test (Morris 1993). For the low-LI study (Figure 3A), the
population mean and standard deviation were estimated at
1.5% and 1.4%, respectively, and the expected treatment effect
was a 2-fold increase in LI. The sample size in each group pro-
viding an 80% chance at a .05 significance level to detect a sta-
tistically significant difference was 10 after adjusting for
multiple comparisons. For the high-LI study (Figure 3B), the
FIGURE 3.—Distribution and range of proliferation labeling index (LI)
data in different tissue types. (A) Ki-67 labeling in hepatocytes show-
ing lower LI control and response values and larger sample size (n ¼
10/group). (B) Ki-67 labeling in uterine glands showing higher LI val-
ues and response range and lower sample size (n ¼ 5–6/group). con ¼
control; d1–d3 ¼ dose groups; t1–t3 ¼ treatment groups. *p < .05
compared to control group.
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population mean and standard deviation were estimated at 9%
and 14%, respectively, and the expected treatment effect was a
3.5-fold increase. Here, the sample size in each group required
for 80% power was only 5. These data sets highlight the impor-
tance of using either historical or pilot data of the target cell
population to assess both variance and range of LIs. When pre-
senting LI data, it is recommended that actual means are given
with standard deviation or standard error values rather than
simple fold-change values from control (especially when LIs
are low). As described earlier, presenting only the total positive
cells per field (rather than LI) is not sufficient for standard anal-
yses, since this metric may be biased by shifts in the total num-
ber of cells/nuclei present in each field.
Complementary Markers
As with other potential treatment effects, cell proliferation
data should be considered in context of other information about
a given compound. Relevant effects may include gross and his-
topathological lesions (e.g., necrosis) and changes in organ
weights, circulating hormones, gene expression markers, and
biochemical or cell-based data. This information may help
identify early molecular events associated with a proliferative
signal, distinguish a risk signal from an expected pharmacolo-
gic response, and aid in the interpretation of marginal or equi-
vocal treatment effects on LI.
One of the most common processes evaluated alongside cell
proliferation is apoptotic cell death. Apoptosis plays a central
role in organ homeostasis, and imbalance between apoptosis
and cell proliferation has an established role in tumorigenesis
(McDonnell 1993; Elmore 2007). Many different techniques
are currently used to detect or measure apoptosis. These include
evaluation of cellular morphology, either by light or electron
microscopy; markers of DNA fragmentation (e.g., terminal
deoxynucleotidyl transferase 20-deoxyuridine, 50-triphosphate
nick end labeling [TUNEL]) and repair (e.g., poly-adenosine
diphosphate-ribose polymerase); plasma membrane changes
(e.g., annexin V); and expression of proteins directly involved
in apoptotic pathways (e.g., caspases, Bcl-2, Bax, p53; Elmore
2007). While morphologic evaluations can be used for qualita-
tive identification of apoptotic cells, these molecular indicators
of apoptosis are generally required to demonstrate quantitative
dose-related changes.
The most widely used IHC marker in toxicological evalua-
tions for in situmeasurement of apoptosis LI is TUNEL, which
labels 30 hydroxyl ends of fragmented chromatin from cells in
the late stages of apoptosis (Negoescu et al. 1996). Due in part
to off-target TUNEL staining in necrotic cells (due to endogen-
ous endonuclease activity), the use of cleaved caspase 3 (CC3)
has gained in popularity as a more specific IHC label for apop-
totic cells (Gown and Willingham 2002). Assays for both
TUNEL and CC3 IHC are applicable to standard FFPE tissues,
and positively labeled cells are typically discrete and readily
quantified.
Many of the pre-analytical and cell counting issues for mea-
suring apoptosis LIs are similar to those described earlier for
cell proliferation. Here, we will only highlight a few considera-
tions that relate more specifically to the use of apoptosis LI
data. Probably the most important issue related to cancer
assessment is the fact that for certain tumorigenic agents the
effect in question is apoptosis inhibition rather than induction.
A classic example is 2,3,7,8-tetrachlorodibenzo-p-dioxin,
which inhibits apoptosis and alters proliferation in the liver via
activation of the aryl hydrocarbon receptor (AhR) pathway
(Budinsky et al. 2014). The challenge here is that basal apop-
tosis indices are very low in many adult (nonlymphoid) tissue
types (often <0.1%), making it unfeasible in many cases to
show a statistically significant decrease in LI in normal cells.
In some cases, an inhibitory effect on apoptosis LI may only
be observable in specific cell populations such as preneoplastic
hepatic foci (Stinchcombe et al. 1995; Budinsky et al. 2014).
Given these low LIs, it is often necessary to count more cells
for apoptosis compared to proliferation markers. Other poten-
tial issues related to apoptotic cell LIs, particularly with
TUNEL, include cross-reactivity with cells undergoing necro-
sis or DNA repair, fixation and pretreatment effects on detec-
tion of DNA strand breaks, and sensitivity and specificity of
the end-labeling technique.
CURRENT APPLICATIONS OF CELL PROLIFERATION DATA
Cell proliferation data are most commonly used in cancer
risk assessment to evaluate the MOA for a specific tumor out-
come observed in a rodent carcinogenicity study (Boobis et al.
2006; EPA 2005). Establishing the key events in an MOA
allows for assessment of human health relevance, dose–
response extrapolation, and identification of potential suscepti-
ble populations (EPA 2005). Weight-of-evidence evaluations
of key events in a putative MOA include strength, consistency,
and specificity of effects; dose–response and temporal relation-
ships; biological plausibility and coherence; and alternative
MOAs (Sonich-Mullin et al. 2001; Boobis et al. 2006). Kinetic
and dynamic factors and no observed adverse effect levels
(NOAELs) are also used to evaluate the plausibility of tumori-
genic effects relative to potential human exposure and whether
or not the MOA events are rodent-specific (Boobis et al. 2006;
Cohen et al. 1991, 2004; Cohen and Ellwein 1990).
Traditional MOAs for carcinogenicity can be broadly divided
into mutagenic and non-mutagenic categories (Weisburger and
Williams 1981; Cohen and Ellwein 1990; Boobis et al. 2006;
Preston 2013). Mutagenic MOAs operate through DNA damage
(as a primary event), while non-mutagenic MOAs occur most
commonly via mitogenesis or cytotoxicity-induced cell prolif-
eration. Select examples of established non-mutagenic MOAs
are listed in Table 2. Resistance to apoptosis is a hallmark of can-
cer cited in some MOAs as an ancillary event, but few published
MOAs appear to act solely through this mechanism (i.e., without
concomitant effects on proliferation).
To examine the role of quantitative proliferation data in can-
cer MOA evaluation, a survey was recently conducted of pes-
ticides previously assessed by the U.S. Environmental
Protection Agency (EPA; Lake et al. 2014). The most common
10 WOOD ET AL. TOXICOLOGIC PATHOLOGY
tumor site for proposed MOAs was liver. Of the 21 compounds
with liver tumor MOAs, 16 had MOAs accepted by the EPA
using current guidelines (EPA 2005). Mitogenic MOAs were
predominant, and a significant increase in proliferation as mea-
sured by BrdU, Ki-67, or PCNA LI was observed at7 days for
all but one of these compounds with accepted MOAs. In con-
trast, short-term effects on proliferation LI were inconclusive
or not provided for all unaccepted MOAs. Notably, the percent-
age of rodent liver tumorigens classified as likely human carci-
nogens was markedly lower among compounds with an accepted
liver tumor MOA compared to those without an accepted MOA.
Proper demonstration of tumorigenic MOAs, and exclusion
of alternative MOAs, includes quantitative cell proliferation
data in most cases in which there is not a clear diagnosis of
hyperplasia on histopathology. For non-genotoxic carcinogens,
tumors occur at detectable incidences at the same, and often
only at higher, doses than early key events such as prolifera-
tion. Establishing the lowest effect levels for these events thus
provides a rationale for a biological threshold underlying a par-
ticular tumor outcome and a basis for the reference dose or con-
centration. Even for tumorigens with evidence of genotoxicity,
proliferation data may be needed to evaluate alternative non-
genotoxic MOAs (Cohen and Ellwein 1990). Following are 2
case examples illustrating how proliferation data have been
used to assess MOAs and evaluate human relevance of tumor
outcomes in rodent carcinogenicity studies.
Mitogenesis
Mitogenic carcinogens typically operate through hormonal or
growth factor receptors. Examples of hormonal mitogens
include estrogens in the uterus, thyroid-stimulating hormone
(TSH) in thyroid follicular cells, and gonadotropins in the
gonads. Nonhormonal mitogens include various endogenous
growth factors (e.g., epidermal growth factor, tumor necrosis
factor a) and xenobiotic agents that activate receptors such as
constitutive androstane receptor (CAR) and PPARs, most promi-
nently in the liver (Holsapple et al. 2006). Disruption of endo-
crine axes may also lead indirectly to mitogenesis. Common
examples here include xenobiotic-induced liver metabolism of
thyroid hormones leading to increased TSH and secondary thyr-
otropism and alteration of the hypothalamic–pituitary–gonadal
axis leading to increased luteinizing hormone (LH) release and
interstitial cell hyperplasia and neoplasia in the testes.
One of the most widely studied mitogenic rodent carcino-
gens is phenobarbital (PB), which was identified decades ago
as a liver tumor promoter in mice (Elcombe et al. 2014). Acti-
vation of CAR has been shown to be the initiating requisite
event in the tumorigenic MOA for PB, followed by increased
hepatocyte proliferation, preneoplastic foci, and tumors (Hol-
sapple et al. 2006; Elcombe et al. 2014). Pregnane X receptor
(PXR) activation, cytochrome P450 enzyme induction, hepato-
cellular hypertrophy, and increased liver weight are considered
to be associative events for CAR activation but not necessarily
requisite key events (Elcombe et al. 2014).
Historically, PB has been an important reference agent in
establishing the concept that some rodent tumor outcomes have
low human health relevance (Elcombe et al. 2014). Epidemio-
logic data based on decades of PB use as a human pharmaceu-
tical showed no evidence of increased liver tumor risk (IARC
2001), and experimental studies in mice lacking CAR and PXR
did not exhibit hypertrophic or proliferative responses to PB
(Ross et al. 2010). While the human liver expresses CAR and
PXR, receptor activity is markedly lower than in rodents. These
findings were supported by studies in mice expressing human
CAR/PXR, which showed increased liver weight and enzyme
induction without liver cell proliferation (as measured by
BrdU LI) in response to PB (Ross et al. 2010). A more recent
study further demonstrated that PB-related metabolic effects
occurred in human cells in a chimeric mouse model, but with-
out the proliferative effect (Yamada et al. 2014). This lack of
proliferation in humanized models helped demonstrate the con-
cepts that increased proliferation is an essential threshold-
based event for mitogenic tumorigens and that early key events
can be used to evaluate human relevance.
Cytotoxicity
The other major category for non-genotoxic tumorigens is
chronic cytotoxicity. Key events in this MOA include necrosis
TABLE 2.—Select examples of non-genotoxic modes of action for rodent tumor outcomes mediated by either mitogenic or regenerative
proliferation.
Organ: cell target Early key event/events Index agent Reference
Mitogenic proliferation
Liver: Hepatocyte Receptor activation > CYP induction Phenobarbital Elcombe et al. (2014)
Lung: Bronchiolar ept Club cell metabolism Isoniazid IARC (1987)
Testes: Leydig cells HPG disruption > Increased LH Flutamide Cook et al. (1999)
Thyroid: Follicular ept HPT disruption > Increased TSH Thiazopyr Dellarco et al. (2006)
Regenerative proliferation
Liver: Hepatocyte Sustained cytotoxicity > Liver cell necrosis Thiamethoxam Pastoor et al. (2005)
Kidney: Tubular ept CYP2E1 metabolism > Tubular cell necrosis Chloroform Golden et al. (1997)
Nasal cavity: Squamous ept Sustained cell death Acetochlor Genter et al. (2000)
Urinary bladder: Urothelial ept Calculi > Urothelial cell death Sodium saccharin Cohen et al. (1991)
Note: CYP ¼ cytochrome P450; ept ¼ epithelium; HPG ¼ hypothalamic pituitary gonadal; LH ¼ luteinizing hormone; TSH ¼ thyroid-stimulating hormone.
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(in rare cases apoptosis) with consequent growth factor signals
leading to regenerative cell proliferation. This process is fre-
quently, but not always, associated with inflammation, depend-
ing on the extent of the tissue damage. A classic case study of
this MOA is sodium saccharin, which was shown in early car-
cinogenicity studies to induce urinary bladder tumors in rats.
Mechanistic studies indicated that these tumors were associ-
ated with calcium phosphate-containing microcrystals that
formed when high oral consumption of sodium saccharin pro-
duced a highly osmolar alkaline environment with high cal-
cium and phosphate and urinary pH >6.5 (specific to the rat;
Cohen et al. 1991; IARC 1999a). The crystals induce damage
of the superficial urinary bladder epithelial cells leading to
chronic regenerative cell proliferation and eventually tumors.
Treatments that acidify urine inhibit the crystal formation,
urothelial toxicity, cell proliferation, and tumor formation (Ell-
wein and Cohen 1990; IARC 1999a, 1999b). Crystal formation
and bladder epithelial proliferation were not observed in stud-
ies of mice or nonhuman primates (Takayama et al. 1998), and
no clear evidence of bladder carcinogenicity was demonstrated
in human epidemiologic studies (Weihrauch and Diehl 2004;
IARC 1999b; Elcock and Morgan 1993). As with the mitogenic
example for PB, the tumorigenic effects of sodium saccharin
were contingent upon the increase in urothelial cell prolifera-
tion observed specifically in rats (Ellwein and Cohen 1990).
FUTURE APPLICATIONS OF CELL PROLIFERATION DATA
One of the primary goals of predictive toxicology is to
facilitate a transition in safety assessment from traditional his-
topathology outcomes to more expedient toxicity pathway-
based end points (Thomas et al. 2013). The scope of the MOA
framework has recently been expanded to incorporate this type
of approach and the broad range of data types required (Meek
et al. 2014). These ideas have also been integrated recently into
the adverse outcome pathway (AOP) construct, which is con-
ceptually similar to an MOA but designed for more prospective
or predictive applications (Ankley et al. 2010; OECD 2012). A
primary aim of the modified MOA and AOP frameworks is to
integrate quantitative data into models that link early events
with more chronic health outcomes using probabilistic relation-
ships (Simon et al. 2014). In the future, it is expected that these
pathway-based models will have an increasingly prominent
role in hazard identification, chemical prioritization for testing,
and safety assessment (Thomas et al. 2013).
For cancer risk assessment, this ‘‘reverse engineering’’
approach would involve initial evaluation of more chemicals
or drugs in the absence of 2-year rodent bioassay data. Current
prospective risk models for cancer can be broadly divided into
negative predictive and prioritization categories. The ultimate
goal of negative predictive cancer models is not to predict spe-
cific tumor outcomes in rodents but to use short-term data to
determine whether oncogenicity studies would likely be nega-
tive or of little value to human health risk assessment (Sistare
et al. 2011; Reddy et al. 2010; Cohen 2004, 2010; Boobis
et al. 2006; Meek et al. 2014). This type of evaluation would
incorporate various data types, including pharmacological
activity, genotoxicity, hormonal effects, subacute histopatholo-
gical effects, and, in some cases, targeted assays related to cell
proliferation (Cohen 2004; Morton, Bourcier, and Alden 2013).
A formal strategy based on this concept was submitted in
2013 as a proposal to change the current International Confer-
ence on Harmonization S1 guidance on rodent carcinogenicity
testing of pharmaceuticals (FDA 2013). Under the proposed
changes, data from non-carcinogenicity studies would be sub-
mitted as part of a Cancer Assessment Document (CAD) that
would justify whether or not a 2-year rat bioassay would affect
the overall human cancer risk assessment of a compound. As
outlined, these CADs may include specific mechanistic targets
as well as data from emerging technologies and alternative test
systems (FDA 2013). This evidence would then be used to
explain or predict potential carcinogenic pathways affected
by the compound and characterize their potential relevance to
human cancer risk. In this negative predictive setting, the main
uses of proliferation data would be to clarify a potential risk
signal (e.g., increased organ weight) or support an MOA of low
concern for human cancer risk.
The second modeling strategy applies mainly to environ-
mental chemicals with limited safety data. In this approach,
high-throughput screening assays and other short-term models
would be used to identify early molecular events potentially
associated with cancer risk. Initial data may come from in vitro
assays for nuclear receptor or growth factor receptor activity,
structure–activity relationships, in silico and tissue culture
models, acute in vivo transcriptomic profiles, and other systems
designed to profile large numbers of compounds in a short
period of time. This information would be used to categorize
biological activity, pathway targets, and dose potency in refer-
ence to known tumorigens and non-tumorigens, and computa-
tional models would be applied to identify risk signals and
inform which compounds require additional testing (Klein-
streuer et al. 2013; Meek et al. 2014; Thomas et al. 2013;
Gusenleitner et al. 2014). While not clearly defined, short-
term proliferation LI data in this prioritization setting would
likely serve as a second-tier functional end point to evaluate
a potential risk signal (e.g., receptor activation) and establish
a dose response. An initial evaluation of human relevance
could then be conducted based on the presence or absence of
these earlier key events.
A central premise for these prospective strategies is that pro-
tecting against requisite early key events in carcinogenesis will
protect against the tumor outcome itself. Consider, for exam-
ple, an agent that has structural alerts and transcriptomic sig-
nals for thyroid activity. A short-term rat study shows
increased hypertrophy and proliferation LI of follicular epithe-
lial cells, and follow-up evidence indicates inhibition of iodide
pump activity, decreased thyroid hormone synthesis, and
increased TSH release from the pituitary gland. If no genotoxi-
city concerns are present, then reference dose estimates would
likely be based on these short-term thyroid effects, regardless
of whether a thyroid tumor outcome was later observed in a
2-year rat carcinogenicity study. A similar scenario could be
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constructed for other rodent tumor outcomes with established
MOAs/AOPs. In many of these cases, proliferation LIs could
serve as the functional end point for dose response estimates,
as in traditional MOA evaluations.
There are a number of important issues that need to be
addressed to increase the usefulness of these prospective
models (Tice et al. 2013). Perhaps the most critical challenge
is establishing when an early molecular signal is specific to an
adverse biological effect (Simon et al. 2014). For prolifera-
tion, many screening assay or genomic signals may not neces-
sarily lead to increased LI, and many responses in LI may not
necessarily lead to cancer. Proliferation by itself does not
imply carcinogenesis risk and in many cases may represent
an expected physiologic or therapeutic response for some tar-
geted pharmaceuticals (e.g., induction of erythroid hyperpla-
sia in bone marrow by erythropoietin-stimulating therapies
for anemia). Future models of cancer risk assessment will
need to reconcile this balanced accuracy issue, providing ade-
quate sensitivity while still discriminating adverse signals
from incidental or adaptive ones. In the near term at least, this
will require better integration of data from higher throughput
systems, short-term functional end points like proliferation,
and traditional morphologic outcomes.
SUMMARY AND CONCLUSIONS
Cell proliferation data play an important role in the evalua-
tion of tumor outcomes observed in carcinogenicity studies.
This application is based on extensive evidence indicating that
increased proliferation LIs represent a necessary precursor
event for most non-genotoxic carcinogens. Dose thresholds
based on LIs (or associated changes) thus provide a way to
assess and protect against cancer risk from chemical exposures.
The proper interpretation of LI data and use in risk assessment
requires an understanding of the different markers, technical
variables, and analytical methods. In this article, we have
reviewed many of these issues and highlighted considerations
for better design of targeted proliferation studies.
As toxicological science moves to more predictive
approaches, new roles will emerge for proliferation data as
short-term quantitative and functional end points. Future mod-
eling work in this area will enable more accurate risk predic-
tions of carcinogenicity based on short-term bioactivity
profiles and better define conditions in which rodent carcino-
genicity studies add value to human cancer risk assessment.
These efforts should benefit from improved standardization
of proliferation LI methods across laboratories, more efficient
tools for measuring proliferation LIs, and more explicit criteria
for discerning true positive risk signals.
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